Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Congresses
Transthyretin Amyloidosis (ATTR)
American Heart Association (AHA) 2025
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2025
Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Transthyretin Amyloidosis (ATTR)
Canadian Association for Population Therapeutics (CAPT) 2025
Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2025
Transthyretin Amyloidosis (ATTR)
Peripheral Nerve Society (PNS) 2025
Publications
Transthyretin Amyloidosis (ATTR)
Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A
Neurology and Therapy
Transthyretin Amyloidosis (ATTR)
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis
Journal of Clinical Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Patisiran on Polyneuropathy of Hereditary Transthyretin Amyloidosis in Patients with a V122I or T60A Variant: A Phase IV Multicenter Study
Annals of Medicine
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
